Skip to content

Evaluation of the Structure Modifying Effect of Avocado-Soybean Unsaponifiables in Hip Osteoarthritis

Evaluation of the Structure-modifying Effect and Safety of Avocado-Soybean Unsaponifiable (Piascledine 300) in Hip Osteoarthritis (OA) a 3 Years Multicenter Randomized, Double Blind, Placebo Controlled Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01062737
Acronym
ERADIAS
Enrollment
Unknown
Registered
2010-02-04
Start date
1999-12-31
Completion date
2006-09-30
Last updated
2010-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Osteoarthritis

Brief summary

This study aims to assess the long term (three years) ability of ASU (Avocado Soya unsaponifiable) to slow the decrease of radiographic JSW (Joint Space Width) in hip osteoarthritis (OA). This is a randomized, double blind, comparative, parallel group study versus placebo.

Detailed description

Inclusion criteria: Primary hip OA, fulfilling ACR criteria, patient over 45 y, painful \> 1 year, Lequesne's index \> or equal to 3, with minimum JSW at the target hip \> 1 mm and \< 4 mm on pelvic radiograph. Primary criterion of efficacy: The main criterion of efficacy is the change of JSW between baseline and end point. JSW is measured on the narrowest joint on pelvic or target hip X ray by blinded reader. Randomisation is stratified according JSW at baseline (\< 2,5 mm or \> or equal to 2,5 mm). Statistical analysis: The Full Analysis Set (FAS) is defined by patients with at least one baseline value and one post baseline value. The main analysis is scheduled on FAS using a Missing At Random (MAR)with a multiple model repeated measure (MMRM)to take in account missing value. SAP (Statistical Analysis Plan) schedule to analyse JSW change as quantitative variable using an ANCOVA and as qualitative variable (progressors defined as JSW loss upper than 0,5 mm) using Mantel Haentzel test.

Interventions

DRUGASU

Sponsors

Laboratoires Expanscience S.A.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* primary OA of hip, * ACR criteria, * older than 45 years, * symptomatic painful \> 1 an, * Lequesne's index \> or equal to 3, * JSW between 1 and 4 mm on pelvic radiograph.

Exclusion criteria

* secondary OA.

Design outcomes

Primary

MeasureTime frame
The main criterion of efficacy is the change of JSW between baseline and end point. JSW is measured on the narrowest joint on pelvic or target hip X ray by blinded reader.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026